<DOC>
	<DOCNO>NCT01199744</DOCNO>
	<brief_summary>To collect background information patient receive prescription Relenza® study risk factor etc . adverse drug reaction collect spontaneous reporting . In particular , characterize type incidence adverse event , serious adverse event , adverse drug reaction investigate risk factor patient population regard high risk novel influenza A ( H1N1 ) use experience Relenza® enough ( pregnant woman , infant , elderly person , decrease physical function ) accordance PFSB/SD Notification 0904 , No.2 Safety Division , Pharmaceutical Food Safety Bureau , MHLW , date 4th September 2009 . To compare data safety data collect overseas sentinel site monitoring program .</brief_summary>
	<brief_title>Relenza® Sentinel Site Monitoring Program Japan</brief_title>
	<detailed_description>1 . Objectives To collect background information patient receive prescription Relenza® study risk factor etc . adverse drug reaction collect spontaneous reporting . In particular , characterize type incidence adverse event , serious adverse event , adverse drug reaction investigate risk factor patient population regard high risk novel influenza A ( H1N1 ) use experience Relenza® enough ( pregnant woman , infant , elderly person , decrease physical function ) accordance PFSB/SD Notification 0904 , No.2 Safety Division , Pharmaceutical Food Safety Bureau , MHLW , date 4th September 2009 . To compare data safety data collect overseas sentinel site monitoring program . 2 . Planned number patient Planned number patient : 1,600 case ( 90 shall pregnant woman ) 3 . Target patient All patient visit sentinel site date contract 31st March 2010 prescribe Relenza® purpose either treatment prophylaxis influenza . 4 . Planned number sentinel sit About 20 site , mainly obstetrics , pediatrics , internal medicine . 5 . Method 1 ) The sentinel sit participate monitoring program select medical institution adopted/purchased Relenza® . Physicians capable fulfil objective program satisfactorily give information concern purpose , target patient , data collect , method , etc . ask cooperation . 2 ) Upon receive consent physician cooperation , write contract conclude head site ( e.g. , hospital director ) collection patient background information start . 3 ) All patient receive prescription Relenza® contract term respective site ( i.e. , date contract 31st March 2010 ) include monitoring program . At sentinel site obstetrics service , pregnant woman receive prescription Relenza® contract term respective site ( i.e. , date contract 31st March 2010 ) include monitor program order focus collection data pregnant woman . 4 ) Physician charge enter data background information patient receive prescription Relenza® date contract 31st March 2010 electronic data collection ( EDC ) system , check data , transmit GlaxoSmithKline K.K . 5 ) The period observation 11 day prescription Relenza® . 6 ) Information case adverse event use Relenza® pregnancy shall report separately spontaneous ADR reporting system . 6.Planned monitoring period November 2009 31st March 2010 The data collection conclude 31st March 2010 requisite number patient accrue ahead schedule . 7.Data collect 1 . Patient identification number identify patient . 2 . Reason use Relenza® ( prophylaxis treatment ) ; Relenza® use treatment : information whether influenza virus test perform clinical laboratory ; yes , result influenza virus test ( Pandemic Flu ( H1N1 ) Seasonal Flu ) . 3 . Patient background information : Birth year , sex ( female : pregnant pregnant , breastfeed breastfeeding ) , body height , body weight , complication ( yes : bronchial asthma , chronic obstructive pulmonary disease , immune deficiency disease [ yes : HIV infection , organ transplant , congenital immunodeficiency , hematological malignancy , autoimmune disease , chemotherapy ] , others ) , route infection ( family infection group infection ) , influenza vaccination status ( vaccinate : date vaccination , generic name brand name vaccine use ) . 4 . Prescription information Relenza® : Relenza® dose , dose frequency per day , Relenza® initiation date , last date administration ) 5 . Date patient contact ; contact patient establish ? ( yes , type contact [ telephone , e-mail , person ] ) . 6 . Adverse event information If adverse event report , information concern circumstance adverse event shall report separately form spontaneous reporting . 7 . Concomitant medication Relenza® treatment ( generic name trade name drug , reason use drug , dose , dose frequency per day , unit , initiation date , last date administration , still medication , use treatment adverse event ) 8 . Completion discontinuation data collection 9 . If Relenza® use pregnancy , course pregnancy delivery , abortion , etc . adverse event observe mother and/or infant shall report separa</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Zanamivir</mesh_term>
	<criteria>Prescribed Relenza® purpose either treatment prophylaxis influenza</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Relenza®</keyword>
	<keyword>SSMP</keyword>
</DOC>